Abstract
the article presents the results of the study of the marketing market of medicines for the treatment of breast cancer in Ukraine during 2019-2020. Medicine treatment schemes based on a clinical protocol were analyzed. On December 1, 2019, 184 drugs were registered for the treatment of breast cancer in Ukraine, and on December 1, 2020 - 194. In 2020, the largest share among of the studied drugs belongs to the group of antineoplastic and immunomodulatory drugs - 82.0 %, and the group of drugs that affect the musculoskeletal system - 18.0 %. On December 1, 2020, drugs were represented by 43 manufacturers, of which 18.6 % were Ukrainian and 81.4 % were foreign. Among Ukrainian companies, the primacy belongs to Pharmex Group LLC (4.1 %), Teva Ukraine LLC (3.1 %) and Farmak JSC (2.6 %). The largest share of foreign suppliers occupies Great Britain - 26.3 %, Switzerland and India by 11.9 %. At that time, in 5 pharmacotherapeutic groups (L01AA01, L01BA01, L01CA04, L01XC07, M05BA03) is not represented by any drug Ukrainian manufacturer. Analysis of the assortment of drugs for the treatment of breast cancer by dosage form in 2020 showed that the main share (35.6 %) is represented by concentrate for solution for infusion, 21.6 % - tablets and 20.6 % - lyophilisate for solution for infusion. Other dosage forms form a total of 22.2 % of the total assortment of drugs, studied in the Ukrainian market.
Highlights
One of the most important medical and social problems in Ukraine and the world is the spread of malignant neoplasms (MN)
Analysis of the range of drugs for the treatment of breast cancer by dosage form in 2020 year showed that the main share (35,6 %) is represented by concentrate for solution for infusion, 21,6 % - tablets and 20,6 % - lyophilisate for solution for infusion
A study of the range of drugs for the treatment of breast cancer, which are registered in the pharmaceutical market of Ukraine in 2019-2020 years
Summary
One of the most important medical and social problems in Ukraine and the world is the spread of malignant neoplasms (MN). The incidence and mortality of the population from malignant neoplasms tend to rapid growth due to internal (age, sex, race, heredity) and external factors (lifestyle, eating habits, long-term medical intervention, such as the use of oral hormonal contraceptives or hormone replacement therapy) (Kamińska, Ciszewski, Łopacka-Szatan, Miotła, Starosławska, 2015). According to the World Health Organization, breast cancer (BC) ranks second in the world among all diseases as one of the most common, after lung cancer. In Ukraine, among the female population of breast cancer ranks first in the structure of cancer morbidity and mortality In connection with the above, the pharmaceutical supply of this group of patients, due to the necessary high-cost treatment, requires the involvement of significant financial resources for chemotherapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
